Dominant Dystrophic Epidermolysis Bullosa
Symptoms, Doctors, Treatments, Advances & More

Dominant Dystrophic Epidermolysis Bullosa Overview

Save information for later
Sign Up

Learn About Dominant Dystrophic Epidermolysis Bullosa

What is the definition of Dominant Dystrophic Epidermolysis Bullosa?
Dominant dystrophic epidermolysis bullosa (DDEB) is a type of epidermolysis bullosa (EB), which is a group of rare inherited conditions in which the skin blisters extremely easily. DDEB is one of the milder forms of EB, although the severity is variable. Blisters may be present at birth, but typically appear during early childhood; occasionally they do not develop until later in life. Blisters often become more numerous and tend to occur over vulnerable sites such as knees, ankles, elbows and knuckles. In adulthood, they usually become less frequent and scars fade. Other signs and symptoms of DDEB may include dystrophic or absent nails, constipation, dental caries and swallowing problems. It is caused by genetic changes in the COL7A1 gene and is inherited in an autosomal dominant manner.
What are the alternative names for Dominant Dystrophic Epidermolysis Bullosa?
  • Dominant dystrophic epidermolysis bullosa
  • Autosomal dominant dystrophic epidermolysis bullosa, Pasini and Cockayne-Touraine types
  • DDEB, Pasini and Cockayne-Touraine types
  • DDEB, generalized
  • DDEB-gen
  • Dominant dystrophic epidermolysis bullosa, generalized
  • Dystrophic epidermolysis bullosa, autosomal dominant
  • Epidermolysis bullosa dystrophica, Cockayne-Touraine type (formerly)
  • Epidermolysis bullosa dystrophica, Pasini type (formerly)
  • Epidermolysis bullosa dystrophica, autosomal dominant
  • Generalized dominant dystrophic epidermolysis bullosa
Who are the top Dominant Dystrophic Epidermolysis Bullosa Local Doctors?
Elite in Dominant Dystrophic Epidermolysis Bullosa
Dr. Anne W. Lucky
Dermatology
Elite in Dominant Dystrophic Epidermolysis Bullosa
Dr. Anne W. Lucky
Dermatology

Dermatologists Of Southwest Ohio, Inc.

7691 5 Mile Road, Suite 312, 
Cincinnati, OH 
513-232-3332
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Anne Lucky is a Dermatologist practicing medicine in Cincinnati, Ohio. Dr. Lucky is rated as an Elite provider by MediFind in the treatment of Dominant Dystrophic Epidermolysis Bullosa. She is also highly rated in 16 other conditions, according to our data. Her clinical expertise encompasses Dystrophic Epidermolysis Bullosa, Epidermolysis Bullosa, Dowling-Meara Epidermolysis Bullosa Simplex, and Dominant Dystrophic Epidermolysis Bullosa. Dr. Lucky is board certified in American Board Of Dermatology and American Board Of Pediatrics. Dr. Lucky is currently accepting new patients.

Elite in Dominant Dystrophic Epidermolysis Bullosa
Catherine Laprise
Elite in Dominant Dystrophic Epidermolysis Bullosa
Catherine Laprise
Saguenay, QC, CA 

Catherine Laprise practices practicing medicine in Saguenay, Canada. Ms. Laprise is rated as an Elite expert by MediFind in the treatment of Dominant Dystrophic Epidermolysis Bullosa. She is also highly rated in 8 other conditions, according to our data. Her clinical expertise encompasses Dowling-Meara Epidermolysis Bullosa Simplex, Dominant Dystrophic Epidermolysis Bullosa, Asthma, and Epidermolysis Bullosa.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in Dominant Dystrophic Epidermolysis Bullosa
Cristina Has
Elite in Dominant Dystrophic Epidermolysis Bullosa
Cristina Has
Hugstetter Str. 55, 
Freiburg, BW, DE 

Cristina Has practices practicing medicine in Freiburg, Germany. Ms. Has is rated as an Elite expert by MediFind in the treatment of Dominant Dystrophic Epidermolysis Bullosa. She is also highly rated in 31 other conditions, according to our data. Her clinical expertise encompasses Epidermolysis Bullosa, Dominant Dystrophic Epidermolysis Bullosa, Dowling-Meara Epidermolysis Bullosa Simplex, and Junctional Epidermolysis Bullosa.

View All Doctors
What are the latest Dominant Dystrophic Epidermolysis Bullosa Clinical Trials?
An International, Multicenter, Randomized, Double-Blind, Parallel Group, Vehicle-Controlled, Phase 2/3 Study With Open-Label Extension Evaluating the Efficacy and Safety of Diacerein 1% Ointment for the Treatment of Generalized Epidermolysis Bullosa Simplex (EBS) [EBShield Study]
An International, Multicenter, Randomized, Double-Blind, Parallel Group, Vehicle-Controlled, Phase 2/3 Study With Open-Label Extension Evaluating the Efficacy and Safety of Diacerein 1% Ointment for the Treatment of Generalized Epidermolysis Bullosa Simplex (EBS) [EBShield Study]
Enrollment Status: Recruiting
Publish Date: April 13, 2026
Intervention Type: Drug
Study Phase: Phase 2/Phase 3

Summary: The proposed Phase 2/3 trial with double-blind and open-label extension phases is an international, multicenter study designed to assess the efficacy and safety of diacerein 1% ointment in patients with generalized EBS.

Match to trials
Find the right clinical trials for you in under a minute
Get started
A Phase II, Closed Label, Placebo Controlled, Randomized, Double-Blinded Clinical Trial to Evaluate the Efficacy and Safety of TolaSure Gel, 5% w/w Targeting Aggregated Mutant Keratin in Epidermolysis Bullosa Simplex (TAMES)
A Phase II, Closed Label, Placebo Controlled, Randomized, Double-Blinded Clinical Trial to Evaluate the Efficacy and Safety of TolaSure Gel, 5% w/w Targeting Aggregated Mutant Keratin in Epidermolysis Bullosa Simplex (TAMES)
Enrollment Status: Recruiting
Publish Date: September 11, 2025
Intervention Type: Drug
Study Phase: Phase 2

Summary: This Phase II clinical study will assess the efficacy, safety and tolerability of topical TolaSure Gel in adults and pediatric patients (4 years of age and older) diagnosed with generalized intermediate to severe epidermolysis bullosa simplex (EBS). Each patient (40 to complete) will be enrolled in the study and will be randomized to receive either TolaSure Gel or a topical Placebo for daily appli...

View All Clinical Trials
Who are the sources who wrote this article ?

Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center